Antiapoptotic cytokines in combination with pegfilgrastim soon after irradiation mitigates myelosuppression in nonhuman primates exposed to high irradiation dose

Hérodin, Françis; Roy, Laurence; Grenier, Nancy; Delaunay, Christophe; Baugé, Stéphane; Vaurijoux, Aurélie; Grégoire, Éric; Martin, Cécile; Alonso, Antonia; Mayol, Jean-François; Drouet, M.

doi:10.1016/j.exphem.2007.04.017

Cited by 47 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The non-parametric Mann-Whitney rank test was used to test the significance between SEG and historical untreated controls. In comparison with 7 Gy irradiated historic untreated controls, 8 SEG treated animals displayed a non-significant reduction in the period of neutropenia (10.7±3. 8 animal cohorts were small, no difference in the former parameters was observed between historical PegG 8 and SEG groups.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys

Drouet¹,

Delaunay²,

Grenier³

et al. 2008

Haematologica

View full text Add to dashboard Cite

Multicytokine therapy may be useful to counteract radiation-induced myelosuppression. We assessed the stem cell factor + glycosylated erythropoietin + pegylated granulocyte colony-stimulating factor combination (SEG) as an emergency treatment. SEG in highly irradiated monkeys efficacy appeared to be restricted to granulopoiesis. Early administration of Erythropoietin did not prevent radiation-induced anemia.Citation: Drouet M, Delaunay C, Grenier N, Garrigou P, Mayol J-F, and Hérodin F. Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys.

show abstract

mentioning

confidence: 99%

“…As far as a tissue protective effect is concerned, we did not observe any early endothelial progenitor cell mobilization or reduction of inflammatory parameters (data not shown). In conclusion, this study shows that SEG would be a poor alternative to SFT3±PegG 8,9 as an emergency treatment. In our conditions, Epo did not improve erythropoietic recovery.…”

mentioning

confidence: 99%

Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys

Drouet¹,

Delaunay²,

Grenier³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…Currently, there are no approved medical countermeasures to alleviate GI syndrome. Several studies have shown that cytokines such as interleukin 11 (IL-11), granulocyte colony-stimulating factor (G-CSF) and basic fibroblast growth factor (b-FGF) could inhibit apoptosis of intestinal epithelial cells and impair radiation-induced intestinal damage [8,9]. However, cytokine treatment is not effective against higher doses of radiation-induced tissue injury.…”

Section: Overview Of Gi Syndromementioning

confidence: 99%

Application of human bone marrow-derived mesenchymal stem cells in the treatment of radiation-induced Gastrointestinal syndrome

Yang

Dai

Chen³

et al. 2014

Sci. China Life Sci.

View full text Add to dashboard Cite

Nuclear accidents and terrorism present a serious threat for mass casualty. Accidental or intended radiation exposure leads to radiation-induced gastrointestinal (GI) syndrome. However, currently there are no approved medical countermeasures for GI syndrome. Thus, developing novel treatments for GI syndrome is urgent. Mesenchymal stem cells (MSCs) derived from bone marrow are a subset of multipotent adult somatic stem cells that have the ability to undergo self-renewal, proliferation and pluripotent differentiation. MSCs have advantages over other stem cells; they can be easily isolated from patients or donors, readily expanded ex vivo, and they possess reparative and immunomodulatory properties. Moreover, MSCs have been shown to be powerful tools in gene therapy and can be effectively transduced with vectors containing therapeutic genes. Therefore, the therapeutic potential of MSCs has been brought into the spotlight for the clinical treatment of GI syndrome. In this review, we discuss the possible role of MSCs in radiation-induced GI syndrome. mesenchymal stem cells, radiation-induced gastrointestinal syndrome, treatment Citation:Yang C, Dai WM, Chen HX, Wu BY. Application of human bone marrow-derived mesenchymal stem cells in the treatment of radiation-induced gastrointestinal syndrome.

show abstract

“…Radiomitigators include immunomodulating agents such as 5-androstenediol, interleukin-12, G-CSF, PEGylated G-CSF, GM-CSF, and CBLB502 (truncated flagellin), as well as and angiotensin-converting enzyme inhibitors (ACE; captopril) (Seed 2005;Dumont et al 2010;Singh et al 2012Singh et al , 2014aMoulder 2014). Radiation therapeutics are agents administered once symptoms manifest in order to accelerate regeneration of tissue and organs Wagemaker et al 1998;Farese et al 2001Farese et al , 2013Drouet et al 2004;Herodin et al 2007;Dumont et al 2010). G-CSF, PEGylated G-CSF, GM-CSF, and cellular therapy falls under this class (Singh et al 2015a).…”

Section: Introductionmentioning

confidence: 99%

A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures

Singh

Seed²

2017

International Journal of Radiation Biology

144

103

View full text Add to dashboard Cite

Purpose: The increasing global risk of nuclear and radiological accidents or attacks has driven renewed research interest in developing medical countermeasures to potentially injurious exposures to acute irradiation. Clinical symptoms and signs of a developing acute radiation injury, i.e. the acute radiation syndrome, are grouped into three sub-syndromes named after the dominant organ system affected, namely the hematopoietic, gastrointestinal, and neurovascular systems. The availability of safe and effective countermeasures against the above threats currently represents a significant unmet medical need. This is the first article within a three-part series covering the nature of the radiation subsyndromes, various animal models for radiation countermeasure development, and the agents currently approved by the United States Food and Drug Administration for countering the medical consequences of several of these prominent radiation exposure-associated syndromes. Conclusions: From the U.S. and global perspectives, biomedical research concerning medical countermeasure development is quite robust, largely due to increased government funding following the 9/11 incidence and subsequent rise of terrorist-associated threats. A wide spectrum of radiation countermeasures for specific types of radiation injuries is currently under investigation. However, only a few radiation countermeasures have been fully approved by regulatory agencies for human use during radiological/nuclear contingencies. Additional research effort, with additional funding, clearly will be needed in order to fill this significant, unmet medical health problem. ARTICLE HISTORY

show abstract

Antiapoptotic cytokines in combination with pegfilgrastim soon after irradiation mitigates myelosuppression in nonhuman primates exposed to high irradiation dose

Cited by 47 publications

References 30 publications

Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys

Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys

Application of human bone marrow-derived mesenchymal stem cells in the treatment of radiation-induced Gastrointestinal syndrome

A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures

Contact Info

Product

Resources

About